Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to boost kidney cancer surgery success

NCT ID NCT07627464

Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal is to see if the combo helps preserve kidney function and reduces complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anlotinib hydrochloride and benmelstobart
What this could lead to
If successful, this approach could improve kidney function preservation and surgical outcomes for patients with localized kidney cancer, potentially reducing the need for more extensive surgery.
What could go wrong
This is an early Phase 2 trial with only 144 participants, so results may not apply to all patients. The combination therapy may cause side effects and may not improve outcomes compared to surgery alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged between 18 and 75 years, inclusive. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 3. Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy. 4. Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 5. No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy. Exclusion Criteria: 1. Subjects with a solitary kidney tumor. 2. Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2). 3. Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau \[VHL\] disease). 4. Subjects with a prior history of renal transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell carcinoma (RCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huadong Hospital Affiliated to Fudan University

    Shanghai, China

  • Hunan Provincial Cancer Hospital

    Changsha, China

  • Jilin Provincial Cancer Hospital

    Changchun, China

  • Liaoning Provincial Cancer Hospital

    Shenyang, China

  • Nanjing Drum Tower Hospital

    Nanjing, China

  • Peking University Third Hospital

    Beijing, China

  • Shanxi Province Cancer Hospital

    Taiyuan, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Yunnan Provincial Cancer Hospital

    Kunming, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.